(Total Views: 451)
Posted On: 04/30/2025 10:03:19 PM
Post# of 154674
March letter & Follow-up:
In the meantime, we will continue discussions with KOLs about the possibility of initiating a follow-up study in patients with mTNBC on an abbreviated timeline, based on currently available data.
April 29, 2025:
*) The Company has also now confirmed survival outcomes in a group of patients with mTNBC and four prior lines of treatment who are alive more than 48 months after receiving leronlimab.
*) CytoDyn has already initiated a follow-up protocol to continue to monitor these surviving patients into the future.
March could have assumed we were maybe pulling from a source of patients outside of Cytodyn. April news made it clear no, we are still using our own patients & data ownership.
36+ & 48+ --- we still own all the data.
That's huge for us.
In the meantime, we will continue discussions with KOLs about the possibility of initiating a follow-up study in patients with mTNBC on an abbreviated timeline, based on currently available data.
April 29, 2025:
*) The Company has also now confirmed survival outcomes in a group of patients with mTNBC and four prior lines of treatment who are alive more than 48 months after receiving leronlimab.
*) CytoDyn has already initiated a follow-up protocol to continue to monitor these surviving patients into the future.
March could have assumed we were maybe pulling from a source of patients outside of Cytodyn. April news made it clear no, we are still using our own patients & data ownership.
36+ & 48+ --- we still own all the data.
That's huge for us.
(7)
(0)
